Chilean Maternal & Infant Cohort Study II (CHiMINCs-II) (CHiMINCs-II)

February 4, 2022 updated by: Dr. Maria Luisa Garmendia, Instituto de Nutrición y Tecnología de los Alimentos

The Chilean Maternal and Infant Nutrition Cohort Study II

The Chilean Maternal & Infant Cohort Study II (ChiMINCs II) is an ongoing cohort that is part of the Chilean Maternal and Infant Nutrition Observatory of the South-East area of Santiago, Chile. In total, 1927 pregnant women beneficiaries of the public health systems and their offspring were recruited before 12 weeks of gestation and are followed across pregnancy (<15, 26-28, and 35-37 weeks of gestation) and up to 2 years of age of their offspring. Two studies are currently nested in ChiMINCs II: 1) Breast Cancer Risk Assessment in Mothers (BRECAM) study, and 2) the ChiMINCs-COVID study. The primary objective of BRECAM study is to test the association between maternal metabolic indicators (i.e., insulin, glucose, IGF-1, and HbAc1 concentrations) at early pregnancy (i.e., <15 and 26-28 weeks of gestation) and breast density 3 months after the cessation of lactation. For this purpose, we collect maternal obstetric, lifestyle, dietary intake, anthropometric, and biochemical information. The aim of the ChiMINCs-COVID study is to assess dietary-related risks and mental health problems derived from the COVID-19 pandemic and their influence on maternal and infant's health and nutrition. Thus, we collected detailed information on dietary behaviors, mental health and COVID-related information at each trimester, along with neonatal and infant nutritional information. The purpose of the present work is to describe the design, methods, and descriptive information at recruitment of ChiMINCs-II, also discussing the implications that this study can have to better understand maternal and infant nutrition and health during the COVID-19 era.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

1927

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Chile
    • Puente Alto
      • Santiago de Chile, Puente Alto, Chile, 8210269
        • Corporación de Salud Municipal de Puente Alto

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

We identified pregnant women who received primary prenatal care within PHCC located in the South East area of Santiago. After, offspring of pregnant women were followed postnatally.

Description

Inclusion Criteria:

  • 18 or more years of age
  • Gestation <15 weeks at first prenatal visit
  • No intention to move outside the city of Santiago in the next to years

Exclusion Criteria:

  • High-risk pregnancy (i.e., preeclampsia, pre- existing diabetes)
  • Pre-existing cancer or family history of breast cancer
  • Intended to migrate from the public to the private health care system

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Mother-infant dyads
Other: Nutrition and mental health during pregnancy
Altered metabolic milieu is defined as a fasting glucose level >100 mg/dL at the first trimester of pregnancy by national guidelines. Altered metabolic milieu during the second trimester (24-28 weeks of pregnancy) is defined as a fasting glucose levels > 92 mg/dL and/or plasma glucose levels > 153 mg/dL two hours after load in the oral glucose tolerance test according to ADA guidelines or a fasting glucose >100 mg/dL and/or > 140 mg/dL two hours after load in the oral glucose tolerance test according to national guidelines. The COVID-19 pandemic is considered as a natural nutritional and mental health exposure.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Breast absolute (AFGV) fibro-glandular volume measured by DXA technique
Time Frame: Three months after breastfeeding cessation
cm3
Three months after breastfeeding cessation
Breast absolute percentage (%FVG) of fibro-glandular volume measured by DXA technique
Time Frame: Three months after breastfeeding cessation
percentage
Three months after breastfeeding cessation
Gestational weight gain
Time Frame: At delivery
kg
At delivery
Gestational Diabetes
Time Frame: At delivery
Percentage of mothers diagnosed
At delivery
Pregnancy Risk Assessment Monitoring System
Time Frame: Through the gestation, up the delivery
Score
Through the gestation, up the delivery
Edinburg Postnatal Depression Scale
Time Frame: Through the gestation, up to 6 months
Score
Through the gestation, up to 6 months
Glucose concentration
Time Frame: Through the gestation, up the delivery
mg/dL
Through the gestation, up the delivery
Insulin concentration
Time Frame: Through the gestation, up the delivery
uIU/mL
Through the gestation, up the delivery
Pandemic Anxiety Scale
Time Frame: Through the gestation, up the delivery
Score
Through the gestation, up the delivery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Offspring weight
Time Frame: At 6 months of age
g
At 6 months of age
Offspring length
Time Frame: At 6 months of age
cm
At 6 months of age
Offspring head circumference
Time Frame: At 6 months of age
cm
At 6 months of age
Offspring body fat
Time Frame: At 6 months of age
Percentage
At 6 months of age

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Instituto de Nutrición y Tecnología de los Alimentos

Collaborators

Pontificia Universidad Catolica de Chile
Servicio de Salud Metropolitano Sur Oriente

Investigators

  • Principal Investigator: María L Garmendia, PhD, Instituto de Nutrición y Tecnología de Alimentos
  • Principal Investigator: Camila L Corvalán Aguilar, PhD, Institute of Nutrition and Food Technology (INTA), University of Chile, Chile
  • Principal Investigator: María F Mujica Coopman, PhD, Institute of Nutrition and Food Technology (INTA), University of Chile, Chile

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 1, 2019

Primary Completion (ANTICIPATED)

July 30, 2022

Study Completion (ANTICIPATED)

April 30, 2023

Study Registration Dates

First Submitted

April 16, 2019

First Submitted That Met QC Criteria

April 16, 2019

First Posted (ACTUAL)

April 18, 2019

Study Record Updates

Last Update Posted (ACTUAL)

February 7, 2022

Last Update Submitted That Met QC Criteria

February 4, 2022

Last Verified

February 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 1190532

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Data and blood samples that will be collected in this study will be under the custody of the principal investigator and a human subject protection review board will regulate its use. Others researchers may access the data by contacting to María Luisa Garmendia (Principal Investigator).

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Nutritional Status

Clinical Trials on Nutrition and mental health during pregnancy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe